Collaboration seeks to improve outcomes for patients with
EGFR-positive non-small cell lung cancer
WASHINGTON, Jan. 25,
2023 /PRNewswire/ -- LUNGevity Foundation is
honored to announce its second research partnership with the EGFR
Resisters in issuing a Request for Application (RFA) for
high-impact research focused on EGFR-positive lung cancer. The EGFR
Resisters is a powerful patient-led community advocating for
improved treatment options for patients with EGFR-positive lung
cancer. This collaboration aims to transform the outcomes for
patients diagnosed with EGFR-positive lung cancer by ultimately
changing EGFR-positive lung cancer into a chronic or curable
condition.
"Over the past decade, we have seen tremendous growth in
personalized treatment options for patients with EGFR-positive
non-small cell lung cancer. These targeted therapies have been
incredibly impactful and effective for many patients," noted
Upal Basu Roy, PhD,
MPH, LUNGevity's executive director of research.
"Unfortunately, we have also seen that tumors treated with these
targeted therapies eventually develop resistance to treatment and
begin to grow again. This award mechanism was developed to identify
and fund research to understand what's next when current treatment
options stop working."
The EGFR Resisters/LUNGevity Research Award Program for
EGFR-Positive Lung Cancer funds high-impact research that seeks to
significantly transform the future for patients diagnosed with
EGFR-positive lung cancer. Projects must directly relate to
improvement of patient outcomes and/or lead to a clinical trial.
This is a $200,000 two-year award.
The program is open to both US and non-US applicants.
"The EGFR Resisters is an incredible community of patients and
caregivers who are fully committed to improving outcomes for others
with EGFR-positive lung cancer," said Dr. Basu Roy. "The projects funded through this
mechanism will be selected by members of the EGFR Resisters
community, along with scientific leaders."
"This research is truly life-or-death for many of us," noted
Jill Feldman, co-founder of the EGFR
Resisters. "It is vitally important that we choose the research
projects very carefully. The EGFR Resisters is grateful to have
LUNGevity's strong vetting process, which uses the same high
standards as the National Institutes of Health, to help guide us in
selecting the most innovative and impactful research."
The EGFR Resisters/LUNGevity Research Award Program for
EGFR-Positive Lung Cancer has a two-step application process. An
applicant must first submit a letter of intent (LOI) due
February 27, 2023. Only a subset of
applicants will be invited to submit a full application after the
LOIs are reviewed; these applications will be due May 8, 2023.
Award recipients are expected to be announced in late summer
2023. For more information about this award, including full
application details, visit www.lungevity.org/egfr-award.
About the EGFR Resisters
The EGFR Resisters is a grassroots community of over 4,000
EGFR-positive lung cancer patients and caregivers from 90+
countries, dedicated exclusively to improving outcomes for people
with EGFR-positive lung cancer by changing EGFR-positive lung
cancer into a manageable, chronic disease. The group uses the
strength of its collaborations to drive important research
questions and fund novel research and clinical trials. For more
information about the EGFR Resisters, please visit
www.egfrcancer.org
About LUNGevity Foundation
LUNGevity Foundation is the nation's leading lung cancer
organization focused on improving outcomes for people with lung
cancer. The foundation works tirelessly to advance research into
early detection and more effective treatments, and to ensure that
patients have access to these advances. LUNGevity seeks to make an
immediate impact on quality of life and survivorship for everyone
touched by the disease—while promoting health equity by addressing
disparities throughout the care continuum. LUNGevity provides
information and educational tools to empower patients and their
caregivers, promote impactful public policy initiatives, and
amplify the patient voice through research and engagement. The
organization provides an active community for patients and
survivors—and those who help them live better and longer lives.
Comprehensive resources include a medically vetted and
patient-centric website, a toll-free HELPLine for support, the
International Lung Cancer Survivorship Conference, and an
easy-to-use Clinical Trial Finder, among other tools. All of these
programs are to achieve our vision—a world where no one dies of
lung cancer. LUNGevity Foundation is proud to be a four-star
Charity Navigator organization.
About Lung Cancer in the US
- About 1 in 16 Americans will be diagnosed with lung cancer in
their lifetime.
- More than 238,000 people in the US will be diagnosed with lung
cancer this year.
- About 60%-65% of all new lung cancer diagnoses are among people
who have never smoked or are former smokers.
- Lung cancer takes more lives in the
United States than the next two deadliest cancers
(colorectal and pancreatic) combined.
- Only about 23% of all people diagnosed with lung cancer in
the United States will survive 5
years or more, BUT if it is caught before it spreads, the chance of
5-year survival improves dramatically.
Please visit LUNGevity.org to learn more.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/egfr-resisters-partners-with-lungevity-to-issue-rfa-for-research-into-egfr-positive-lung-cancer-301730094.html
SOURCE LUNGevity Foundation